Conceptus To Hold Third Quarter Financial Results Conference Call Oct. 24, 2001.Business Editors/Health & Medical Writers SAN CARLOS, Calif.--(BW HealthWire)--Oct. 17, 2001 Conceptus conceptus /con·cep·tus/ (-tus) the product of the union of oocyte and spermatozoon at any stage of development from fertilization until birth, including extraembryonic membranes as well as the embryo or fetus. , Inc. (Nasdaq:CPTS CPTS Certified Penetration Testing Specialist (network security) CPTS Comptroller Squadron CPTS Computer Program Test Specifications CPTS Catastrophe Personnel Tracking System CPTS Claims Procedure Training Specialist ), developer of the non-incisional permanent birth control procedure Essure(TM) pbc, previously known as STOP (Selective Tubal Tubal (t  `bəl), in the Bible, son of Japheth. Occlusion Procedure) non-surgical permanent birth control device for women, today announced that the Company will release 2001 third quarter financial results on Wednesday, Oct. 24, 2001. Steven Bacich, president and chief executive officer, and Glen Furuta, chief financial officer, will host an investment-community conference call beginning at 4:30 p.m. Eastern Time on Oct. 24 to discuss results and to answer questions. Individuals interested in listening to the conference call live via the Internet may do so by visiting www.conceptus.com. A replay will be available on the Website for 30 days. Conceptus, Inc. is developing Essure pbc, an investigational medical device and procedure in the U.S., which is designed to provide a non-surgical alternative to surgical tubal ligation ligation /li·ga·tion/ (li-ga´shun) the application of a ligature. tubal ligation sterilization of the female by constricting, severing, or crushing the uterine tubes. , the leading form of birth control worldwide. The Essure device is a unique and proprietary micro-insert designed to be deployed permanently into each fallopian tube fallopian tube (fəlō`pēən), either of a pair of tubes extending from the uterus to the paired ovaries in the human female, also called oviducts, technically known as the uterine tube. using the Company's minimally invasive transcervical tubal access catheter system. Clinical studies have shown that the Essure device induces a benign occlusive occlusive /oc·clu·sive/ (o-kloo´siv) pertaining to or causing occlusion. oc·clu·sive adj. 1. Occluding or tending to occlude. 2. tissue response once in place. Data from the United Nations show that worldwide, 30% of reproductive couples using contraception rely on surgical tubal ligation. Additionally, a survey performed by the Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC), agency of the U.S. Public Health Service since 1973, with headquarters in Atlanta; it was established in 1946 as the Communicable Disease Center. indicates that surgical tubal ligation continues to be the most prevalent form of contraception in the U.S., and that 35% of women age 35-44 have had a surgical tubal sterilization. An estimated 700,000 surgical tubal ligations are performed each year in the U.S. Additional information about the Company and the Essure device is available at www.conceptus.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion